Left atrial thrombosis despite dabigatran therapy

Anil Pandit; Fayaz A. Hakim; Komandoor Srivathsan; John J. Lynch

Left atrial thrombosis despite dabigatran therapy

Anil Pandit, Fayaz A. Hakim, Komandoor Srivathsan, John J. Lynch

Cardiovascular Diseases

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation..

Original language	English (US)
Pages (from-to)	31-32
Number of pages	2
Journal	Journal of Atrial Fibrillation
Volume	6
Issue number	2
State	Published - Aug 2013

Keywords

Atrial fibrillation
Dabigatran
Left atrial thrombosis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Cite this

@article{9dc1196b1a7348beb158d6e50c1c950e,

title = "Left atrial thrombosis despite dabigatran therapy",

abstract = "Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation..",

keywords = "Atrial fibrillation, Dabigatran, Left atrial thrombosis",

author = "Anil Pandit and Hakim, {Fayaz A.} and Komandoor Srivathsan and Lynch, {John J.}",

year = "2013",

month = aug,

language = "English (US)",

volume = "6",

pages = "31--32",

journal = "Journal of Atrial Fibrillation",

issn = "1941-6911",

publisher = "Cardiofront, Inc.",

number = "2",

}

TY - JOUR

T1 - Left atrial thrombosis despite dabigatran therapy

AU - Pandit, Anil

AU - Hakim, Fayaz A.

AU - Srivathsan, Komandoor

AU - Lynch, John J.

PY - 2013/8

Y1 - 2013/8

N2 - Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation..

AB - Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation..

KW - Atrial fibrillation

KW - Dabigatran

KW - Left atrial thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84883866536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883866536&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84883866536

SN - 1941-6911

VL - 6

SP - 31

EP - 32

JO - Journal of Atrial Fibrillation

JF - Journal of Atrial Fibrillation

IS - 2

ER -

Left atrial thrombosis despite dabigatran therapy

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this